Followers | 128 |
Posts | 2150 |
Boards Moderated | 1 |
Alias Born | 12/27/2007 |
Friday, December 22, 2017 1:34:02 PM
https://moneymorning.com/2017/12/21/5-top-biotech-penny-stocks-to-buy-with-huge-catalysts-in-january-2018/
Currently trading at $4.85, Manhattan-based Axsome Therapeutics Inc. (Nasdaq: AXSM) makes drugs to treat depression, Alzheimer's disease, and chronic pain.
Unlike other biotech penny stocks, shares of AXSM aren't "all in" on just one drug's results.
Axsome has at least three different drugs in clinical trial testing, meaning it has a greater chance of having at least one of its drugs pass. This makes shares of AXSM less risky than a biotech penny stock with only one drug in development.
Specifically, we're going to focus on Axsome's AXS-02 drug, which is in two separate phase 3 clinical trials to treat complex regional pain syndrome and knee osteoarthritis associated with bone marrow lesions. The results for these two clinical trials are expected in late December or early January.
If the AXS-02 drug passes phase 3 clinical trials, the stock could jump significantly.
The company also has a second drug, AXS-05, currently in phase 3 clinical trials for the treatment of treatment-resistant depression. Those results are expected sometime in the first half of 2018, so it's likely that AXS-02's results will come out first.
The next company we'll show you is the cheapest on this list…
Recent AXSM News
- Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024 • GlobeNewswire Inc. • 09/24/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/04/2024 11:05:39 AM
- Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine • GlobeNewswire Inc. • 09/04/2024 11:00:00 AM
- Axsome Therapeutics to Participate in Investor Conferences in September • GlobeNewswire Inc. • 08/27/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2024 11:05:55 AM
- Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc. • GlobeNewswire Inc. • 08/21/2024 11:00:39 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 11:27:21 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/09/2024 09:07:28 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/05/2024 08:36:25 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/05/2024 08:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 11:05:45 AM
- Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/05/2024 11:00:00 AM
- U.S. Index Futures and Oil Prices Plunge on Recession Concerns • IH Market News • 08/05/2024 09:46:20 AM
- Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5 • GlobeNewswire Inc. • 07/11/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 08:31:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:30:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 11:38:42 AM
- Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories • GlobeNewswire Inc. • 06/05/2024 11:35:00 AM
- Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month • GlobeNewswire Inc. • 06/04/2024 11:00:00 AM
- Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month • GlobeNewswire Inc. • 06/03/2024 11:00:00 AM
- Axsome Therapeutics to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 05/30/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 12:12:56 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 12:11:32 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/29/2024 08:24:17 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/29/2024 08:23:38 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM